A major concern to global health, antimicrobial resistance (AMR) reduces the effectiveness of antibiotics and other antimicrobial medicines, increasing treatment failures and mortality rates. The misuse of antibiotics in agriculture and healthcare, poor sanitation, and the slow development of novel antimicrobial medicines are some of the reasons contributing to the fast evolution of resistant microorganisms. This article looks at the main processes that lead to antimicrobial resistance, such as biofilm formation, horizontal gene transfer, and genetic changes. It also looks at cutting-edge treatment strategies like bacteriophage therapy, combination medicines, and antimicrobial peptides (AMPs) that try to stop AMR. While phage therapy uses bacteriophages to specifically target and kill bacteria, AMPs offer a special mode of action that targets microbial membranes. Additionally, combination medicines are becoming more popular, especially those that combine conventional antibiotics with non-antibiotic adjuvants or resistance-modifying compounds to increase the effectiveness of existing medications and postpone the establishment of resistance. This article provides a thorough examination of these methods, highlighting potential tactics and new lines of inquiry that may be able to lessen the AMR epidemic and protect public health. Mitigating AMR in the future will necessitate a multipronged strategy that includes both innovative treatments and calculated policy changes to manage resistance.
Khuspe et al. (Thu,) studied this question.